Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Acquire Norwegian Magnetic Bead Maker Dynal Biotech for $380M

NEW YORK, Feb. 8 (GenomeWeb News) - Invitrogen plans to purchase Norwegian magnetic bead maker Dynal Biotech from its majority owner, Nordic Capital, and a co-investor for 2.5 billion Norwegian kroner ($380 million), the company said today.

 

Dynal Biotech, based in Oslo, provides magnetic bead-based separation technologies that are used in cell separation and purification, cell stimulation, protein research, nucleic acid research, and microbiology.

 

Invitrogen plans to integrate the company's Dynabead technology to enhance its own products for assay development, RNA interference, DNA cloning, proteomic analysis, and screening applications. It also plans to couple Dynabeads with targeted antibodies from Zymed Laboratories, another company Invitrogen is currently acquiring.

 

The acquisition is scheduled to close by the end of March. Invitrogen expects Dynal, which has more than 400 employees in Norway, the US, the UK, and China, to create $74 million in revenues from April until the end of the year.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.